Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III–IV intermediate- and high-grade non-Hodgkin's lymphoma (1997)
    Springer
    Annals of oncology 8 (1997), S. 67-70 
    Details
    ISSN: 1569-8041
    Keywords: chemotherapy ; CHVmP-VB ; EORTC ; intermediate/high-grade ; non-Hodgkin's lymphoma
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract CHOP has been and still is regarded by many as the ‘standard’ treatment ofadvanced non-Hodgkin's lymphoma. In 1980 the EORTC Lymphoma Cooperative Groupstarted a study to evaluate the addition of vincristine and bleomycin to itsstandard four-drug combination chemotherapy, CHVmP (cyclophosphamide,hydroxorubicin, Vm-26, prednisone). Eligible patients were stage III or IV,intermediate- to high-grade non-Hodgkin's lymphoma (Working FormulationE–I). One-hundred-eighty-nine patients were entered, of whom 140 were eligibleand evaluable. A previous report showed an improved response rate andfailure-free survival (FFS) and overall survival for the combination CHVmP-VB. At ten years, the outcome still favors the addition of vincristine andbleomycin. The FFS was 34% vs. 23% and the overall survival34% vs.22%. This difference was mainly due to a difference in CR rate(74% vs.49%), Relapse-free survival for patients reaching a CR was the same inboth arms. When the patients were grouped according to the International PrognosticFactor Index, no statistically significant difference could be observed infavor of one treatment within either group. This trial clearly demonstrates the benefit gained by the addition ofvincristine and bleomycin to ‘standard’ chemotherapy for intermediate andhigh-grade non-Hodgkin's lymphoma.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008210102316
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Is the Durie and Salmon diagnostic classification system for plasma cell dyscrasias still the best choice? (1995)
    Springer
    Annals of hematology 70 (1995), S. 19-24 
    Details
    ISSN: 1432-0584
    Keywords: Key words Multiple myeloma ; Smoldering multiple myeloma ; Indolent multiple myeloma ; Monoclonal gammopathy of undetermined significance ; Classification systems
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary  There are a number of systems for diagnosing multiple myeloma, myeloma variants and monoclonal gammopathy of undetermined significance. We compared three systems, those according to Durie and Salmon, to Kyle and Greipp, and to the British Columbia Cancer Agency, using material from a population-based registry of 847 patients with a paraproteinemia or multiple myeloma. Of these, 157 underwent both bone marrow and X-ray examinations and were subsequently included in our analysis. The differences between the systems were small, even though in only 64% of the cases the diagnosis according to all three systems was identical. The system used by the British Columbia Cancer Agency turned out to be the shortest and easiest system reviewed here. We propose a more frequent application of this system instead of the more commonly used Durie and Salmon and Kyle and Greipp criteria.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01715377
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Presenting signs and symptoms in multiple myeloma: High percentages of stage III among patients without apparent myeloma-associated symptoms (1995)
    Springer
    Annals of hematology 70 (1995), S. 149-152 
    Details
    ISSN: 1432-0584
    Keywords: Diagnosis ; Multiple myeloma ; Paraprotein ; Presentation ; Signs and symptoms
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract We studied the medical histories of 127 patients diagnosed with multiple myeloma included in a population-based registry of 945 patients with a paraprotein or multiple myeloma in the region of the Comprehensive Cancer Center West (CCCW). We defined patients “not immediately diagnosed” or “delayed diagnosis” as those patients in whom myeloma was not included in the initial differential diagnosis. We found that 37% belonged to this category. These patients more often had symptoms not associated with multiple myeloma. Since a surprising 51% of patients with delayed diagnosis turned out to have stage-Ill myeloma, the physician should be alert to the presence of this disease, despite the fact that co-morbidity may mask its presence.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01682035
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Presenting signs and symptoms in multiple myeloma: high percentages of stage III among patients without apparent myeloma-associated symptoms (1995)
    Springer
    Annals of hematology 70 (1995), S. 149-152 
    Details
    ISSN: 1432-0584
    Keywords: Key words Diagnosis ; Multiple myeloma ; Paraprotein ; Presentation ; Signs and symptoms
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  We studied the medical histories of 127 patients diagnosed with multiple myeloma included in a population-based registry of 945 patients with a paraprotein or multiple myeloma in the region of the Comprehensive Cancer Center West (CCCW). We defined patients "not immediately diagnosed" or "delayed diagnosis" as those patients in whom myeloma was not included in the initial differential diagnosis. We found that 37% belonged to this category. These patients more often had symptoms not associated with multiple myeloma. Since a surprising 51% of patients with delayed diagnosis turned out to have stage-III myeloma, the physician should be alert to the presence of this disease, despite the fact that co-morbidity may mask its presence.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01682035
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...